Jacobson Center for Clinical & Translational Research

Main Menu


Additional Information


Contact Us


Study Title:  PISCES:  A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment.  (NCT03132675)

Study Purpose:  This will be a Phase 2 study of intratumoral pIL-12-EP plus IV pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on pembrolizumab or nivolumab.

Principal Investigator: John Nemunaitis, MD

Study Coordinator: For more information email Stephanie Smiddy, RN or call 419-383-6962.


Last Updated: 4/26/18